CSI Market
Sign In | Register

Gossamer Bio Inc (GOSS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GOSS Annual Cash Flow →
This cash flow overview for Gossamer Bio Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-99.10
Depreciation & amortization0.01
Amortization of Other Assets5.21
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation8.77
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction42.24
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net-
In Process Research And Development Expenses-
Amortization Of Operating Lease Right Of Use Assets-
Research And Development In Process Expenses-
Operating Lease Right Of Use Asset Amortization Expense0.23
Increase Decrease In Operating Lease Liabilities-0.23
Increase Decrease In Accrued Research And Development Expenses-4.27
Income taxes0.00
Realized Investment Gains (Losses), Total0.00
Accounts Receivable-8.27
Increase (Decrease) in Accounts Payable1.57
Accrued Expense-1.40
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-8.89
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net1.05
Payments for (Proceeds from) Other Operating Activities-19.36
Discontinued operations0.00
Net Cash flow from Operating Activities-78.15
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-24.99
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Securities66.60
Proceeds From Sale Of Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net109.30
Discontinued operations0.00
Net Cash Flow from Investing Activities84.31
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-1.96
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.51
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.18
Payment Of Deferred Offering Costs-
Proceeds From Issuance Of Equity Option-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-2.63
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-78.15
Total Cash Flow3.42
4 historic quarters locked

Sign in to unlock the full Gossamer Bio Inc cash flow history.

Sign In Create Free Account

About Gossamer Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001728117-26-000072

Figures are derived from filed reports and may be restated. Historical data is subject to revision.